Mechanism of action study of anti-IL17 treatment in spondyloarthritis.

• Conditions: Spondyloarthritis; MedDRA version: 16.1Level: LLTClassification code 10032155Term: Other inflammatory spondylopathiesSystem Organ Class: 100000004859; MedDRA version: 16.1Level: LLTClassification code 10070759Term: SpondylopathySystem Organ Class: 100000004859; Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]

• Registration Number: EUCTR2013-002709-79-NL
• Lead Sponsor: Academic Medical Center, Department of Rheumatology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01-16
• Last Update Posted: 10 February 2014

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

-Male or non-pregnant/non-lactating females age 18-70
- Diagnosis of SpA according to ESSG criteria and/or ASAS criteria
- Active disease defined by =1 swollend and = 1 tender joint, and at least 1 swollen knee or ankle joint at baseline
- stable dose of concomitant medication (NSAIDs etc.)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Evidence for infectious or malignant process (on chest X ray/MRI etc)
- Pts taking opioid angalgetics
- Previous IL-17 therapy exposure
- Previous use of celldepleting therapies, biological immunomodulants (except for a.TNF)
- Significant medical problems or diseases

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified